The global lentiviral vector CDMO market is projected to grow at a CAGR of 8% over the next five years. This growth is driven by rising demand for gene and cell therapies, an expanding pipeline of ...
At the core of Creative Biogene’s production process lies an advanced in-house infrastructure, combining premium reagents with a streamlined quality control workflow. This meticulous methodology not ...
High manufacturing costs limit access to cell and gene therapies and make it harder to bring new products to market, according to VIVEbiotech CEO, Jon Alberdi, who says cheaper production processes ...
GERMANTOWN, Md. and PRAGUE, Czech Republic, May 18, 2023 (GLOBE NEWSWIRE) -- (NASDAQ: ORGS) (“Orgenesis”), a global biotech company working to unlock the full potential of cell and gene therapies (CGT ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results